Claims for Patent: 5,716,830

Summary for Patent: 5,716,830

Title:	Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus
Abstract:	Immortalized non-tumorigenic or tumorigenic human prostatic epithelial and fibroblast cell lines and derivatives thereof, containing DNA of a hybrid virus between adenovirus 12 and simian virus 40. The cell lines are useful for research on causes, treatment and prevention of prostate cancer, benign prostatic hyperplasia, male infertility, birth defects, aging and assessment of environmental toxic agents.
Inventor(s):	Webber; Mukta M. (Eagle, MI), Rhim; Johng S. (Potomac, MD)
Assignee:	Board of Trustees operating Michigan State University (East Lansing, MI) The United States of America as represented by the Department of Health (Washington, DC)
Application Number:	08/805,596
Patent Claims:	1. A method for testing carcinogenicity of an agent comprising culturing an immortalized adult human normal prostatic epithelial or fibroblast cell derived cell line free of other cell lines and containing DNA of adenovirus and simian virus 40 as a hybrid virus, the cell line having the identifying characteristics of the prostatic epithelial or fibroblast cell without the hybrid virus in addition to being immortalized by the hybrid virus with an agent suspected of being carcinogenic or exposing the sells to radiation, and determining formation of an abnormal cellular mass by said cell line, the formation of the abnormal cellular mass being indicative of carcinofenicity of said agent. 2. The method of claim 1 wherein a normal tumor suppressor gene is introduced into the cell which results in a loss of tumorigenicity. 3. A method of determining carcinogenicity promoting activity of an agent comprising: a) culturing an immortalized adult human normal prostatic epithelial or fibroblast cell derived cell line free of other cell lines and containing DNA of adenovirus and simian virus 40 as a hybrid virus, the cell line having the identifying characteristics of the prostatic epithelial or fibroblast cell without the hybrid virus in addition to being immortalized by the hybrid virus with an agent suspected of being carcinogenic; and b) measuring a change in phenotypic characteristics of the cell line induced by the agent. 4. The method of claim 3, wherein the phenotypic characteristic is increased urokinase expression, said increase being indicative if carcinogenicity of the agent. 5. The method of claim 3, wherein the phenotypic characteristic is increased type IV collagenase expression, said increase being indicative of promoting activity of the agent or the agent having the ability to enhance tumor progression. 6. The method of claim 1 wherein the simian virus 40 is deposited as ATCC VR-239. 7. The method of claim 1 wherein the adenovirus if adenovirus 12 deposited as ATCC VR-863. 8. The method claim 1 wherein the adenovirus is adenovirus 12 and the simian virus 40 is deposited as ATCC VR-863 and VR-239, respectively. 9. The method of claim 1 wherein the cell line is deposited as ATCC CRL 11611. 10. The method of claim 1 wherein the cell line has the phenotypic characteristics comprising: cytokeratins 8/18 positive, desmin negative, Factor VIII negative, contact inhibited, anchorage dependent, androgen responsive, plasminogen activator secretion normal, collagenase secretion normal, is non-tumorigenic, produces prostate specific antigen and contains a hybrid virus of adenovirus and simian virus 40. 11. The method of claim 1 wherein the cell line produces prostate specific antigen.

Details for Patent 5,716,830

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2014-04-28
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2014-04-28